Asia Pacific Cardiac Marker Testing Market Research Report – Segmented By Type, Product, Disease, Testing & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)
Asia Pacific Cardiac Marker Testing Market Size & Growth (2022 to 2027):
The Size of the Asia Pacific Cardiac Marker Testing Market is valued at USD 0.44 billion in 2022 and is expected to grow to USD 0.76 billion by 2027, registering a CAGR of 11.7% during the forecast period 2022 to 2027.
An increasing number of clinical studies for cardiac biomarker detection and public-private collaborations for cardiac biomarker research are driving the market for cardiac marker testing.
An increase in heart-related diseases and substantial product research and development projects are driving market demand. Consumers are more aware of early detection and the growing need to avoid cardiovascular illnesses such as heart failure, heart attacks, and Acute Coronary Syndrome (ACS). Several Asian Pacific organizations are increasing financing for clinical investigations and research on cardiac marker identification.
Growth in point-of-care testing and rising demand for the most up-to-date treatment processes propel the market forward. In addition, the market is also growing as people become more aware of the benefits of early detection and prevention of heart disorders, including heart attacks.
BNP, along with hs-TNI, - HBDH, CK-MB, and LDH, operates as a predictive biomarker in COVID-19 individuals with or without pre-existing coronary artery disease. With all of these factors in mind, the Asia Pacific Cardiac Marker Testing Market has had moderate growth during the pandemic and is anticipated to increase in the following years. Therefore, these factors will drive the Asia Pacific Cardiac Marker Testing market.
Unfavorable reimbursement policies and strict government rules and regulations are limiting the growth of the Asia Pacific cardiac marker testing market. The cardiac markers aren't employed to diagnose the heart's myocardial blood supply or the tissue location where death occurs. Factors that limit expansion include issues with sample storage and preservation and the amount paid in compensation for suffering. The market is driven by correct and early outcomes and cardiac POC testing.
The cardiac marker testing market witnessed short-term negative growth during COVID-19, which might be attributed to more than a 50% decline in patients with cardiovascular disorders and those diagnosed with myocardial infarction.
This research report on the Asia Pacific Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories.
By Type:
- Troponin I & T
- CK-MB
- Myoglobin
- BNP
- hs-CRP
By Product:
- Reagent
- Instrument
- Chemiluminescence
- Immunofluorescence
- Immunochromatography
- ELISA
By Disease:
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
By Testing:
- Lab
- POC
By Country:
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC
Geographically, the market for cardiac marker testing in the Asia Pacific is expected to develop at the quickest rate. Higher healthcare spending by a more extensive population base, modernization of healthcare infrastructure, and increased penetration of cutting-edge clinical laboratory technologies (mainly in rural regions) are driving the Asia Pacific market.
The India Cardiac Marker Testing Market is predicted to expand at significant growth among all regions of the globe due to variables such as Y-O-Y growth in CVD incidence and a rapid rise in the aging population throughout the forecast period.
The China Cardiac Marker Testing Market is predicted to dominate market share due to the growing understanding of sophisticated technologies among lab workers and cardiologists because of frequent conferences and seminars.
The market growth in APAC is accelerating due to public and private sector initiatives to raise awareness about early disease diagnosis. As a result, according to estimates, annual cardiovascular incidents in China are expected to increase by more than 50% between 2010 and 2030.
As a result, the cardiac marker testing market is booming in APAC, especially in Japan and India. Improving healthcare infrastructure, a significant patient population, and increasing funding and investments for cardiac analyzer upgrades propels the APAC region's market expansion.
KEY MARKET PLAYERS
Notable companies leading the Asia Pacific Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Siemens AG, Danaher Corporation, Alere Inc., , and Guangzhou Wondfo Biotech Co. Ltd, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, bioMérieux SA, Abbott Laboratories.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Reagents and Kits
5.1.3 Instruments
5.1.3.1 Chemiluminescence
5.1.3.2 Immunofluorescence
5.1.3.3 Elisa
5.1.3.4 Immunochromatography
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Troponin I & T
5.2.3 CK-MB
5.2.4 Myoglobin
5.2.5 BNP
5.2.6 hsCRP
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
5.3 Disease
5.3.1 Introduction
5.3.2 Acute Coronary Syndrome
5.3.3 Myocardial Infarction
5.3.4 Congestive Heart Failure
5.3.5 Y-o-Y Growth Analysis, By Disease
5.3.6 Market Attractiveness Analysis, By Disease
5.3.7 Market Share Analysis, By Disease
5.4 Type of Testing
5.4.1 Introduction
5.4.2 Lab
5.4.3 Point-Of-Care Testing
5.4.4 Y-o-Y Growth Analysis, By Type of Testing
5.4.5 Market Attractiveness Analysis, By Type of Testing
5.4.6 Market Share Analysis, By Type of Testing
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Disease
6.1.3.5 By Type of Testing
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Disease
6.1.4.5 By Type of Testing
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Disease
6.1.5.5 By Type of Testing
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Getinge Group
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Medtronic plc
8.3 LivaNova PLC
8.4 XENIOS Roche Diagnostics Ltd.
8.5 Abbott Laboratories
8.6 Siemens AG
8.7 Danaher Corporation
8.8 Alere Inc.
8.9 BioMérieux SA
8.10 LSI Medience Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Asia-Pacific Cardiac Marker Testing Market By Type, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Troponin I & T Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Insulin Delivery Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific CK-MB Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Myoglobin Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific BNP Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific hsCRP Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Cardiac Marker Testing Market By Product, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Reagent Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Instrument Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Chemiluminescence Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Immunofluorescence Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Immunochromatography Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific ELISA Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Cardiac Marker Testing Market By Disease, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Acute Coronary Syndrome Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Myocardial Infarction Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Congestive Heart Failure Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Cardiac Marker Testing Market By Testing, From 2022 to 2027 ( USD Billion )
- Asia-Pacific Lab Market By Region, From 2022 to 2027 ( USD Billion )
- Asia-Pacific POC Market By Region, From 2022 to 2027 ( USD Billion )
- Japan Cardiac Marker Testing Market By Type, From 2022 to 2027 ( USD Billion )
- Japan Cardiac Marker Testing Market By Product, From 2022 to 2027 ( USD Billion )
- Japan Cardiac Marker Testing Market By Disease, From 2022 to 2027 ( USD Billion )
- Japan Cardiac Marker Testing Market By Testing, From 2022 to 2027 ( USD Billion )
- China Cardiac Marker Testing Market By Type, From 2022 to 2027 ( USD Billion )
- China Cardiac Marker Testing Market By Product, From 2022 to 2027 ( USD Billion )
- China Cardiac Marker Testing Market By Disease, From 2022 to 2027 ( USD Billion )
- China Cardiac Marker Testing Market By Testing, From 2022 to 2027 ( USD Billion )
- India Cardiac Marker Testing Market By Type, From 2022 to 2027 ( USD Billion )
- India Cardiac Marker Testing Market By Product, From 2022 to 2027 ( USD Billion )
- India Cardiac Marker Testing Market By Disease, From 2022 to 2027 ( USD Billion )
- India Cardiac Marker Testing Market By Testing, From 2022 to 2027 ( USD Billion )
- Australia Cardiac Marker Testing Market By Type, From 2022 to 2027 ( USD Billion )
- Australia Cardiac Marker Testing Market By Product, From 2022 to 2027 ( USD Billion )
- Australia Cardiac Marker Testing Market By Disease, From 2022 to 2027 ( USD Billion )
- Australia Cardiac Marker Testing Market By Testing, From 2022 to 2027 ( USD Billion )
- South Korea Cardiac Marker Testing Market By Type, From 2022 to 2027 ( USD Billion )
- South Korea Cardiac Marker Testing Market By Product, From 2022 to 2027 ( USD Billion )
- South Korea Cardiac Marker Testing Market By Disease, From 2022 to 2027 ( USD Billion )
- South Korea Cardiac Marker Testing Market By Testing, From 2022 to 2027 ( USD Billion )
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
